Enlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program UpdateGlobeNewsWire • 02/03/21
Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxivGlobeNewsWire • 12/21/20
Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 PatientsGlobeNewsWire • 12/03/20
Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with AllocetraGlobeNewsWire • 11/18/20
Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company's Board of DirectorsGlobeNewsWire • 11/17/20
Enlivex to Present Schedule for Sepsis, COVID-19 and Solid Cancer Programs at H.C. Wainwright's 6th Annual Israel ConferenceGlobeNewsWire • 11/11/20
Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn's Disease, and Ulcerative Colitis with Allocetra ImmunotherapyGlobeNewsWire • 11/05/20
Enlivex: Israeli Ministry of Health Authorizes Initiation of Phase IIb Clinical Trial Evaluating Safety and Efficacy of Allocetra in Sepsis PatientsGlobeNewsWire • 11/03/20
Enlivex Reports Dosing of First Two Patients in Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 PatientsGlobeNewsWire • 10/22/20
Enlivex: After Expedited Review, Israeli Ministry of Health Authorizes Initiation of Phase II Clinical Trial Evaluating Allocetra in COVID-19 Severe and Critical PatientsGlobeNewsWire • 10/13/20
Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical ConditionGlobeNewsWire • 10/01/20
Enlivex Announces Allowance of New Chinese Patent Covering Allocetra ImmunotherapyGlobeNewsWire • 09/16/20
Enlivex Announces Allowance of New U.S. Patent Covering Allocetra ImmunotherapyGlobeNewsWire • 08/25/20
Enlivex Announces a new publication “Apoptotic cell therapy for cytokine storm associated with acute severe sepsis” in Cell Death & Disease, a Nature Research JournalGlobeNewsWire • 07/20/20
Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA ImmunotherapyGlobeNewsWire • 06/18/20
Enlivex Therapeutics to Present at the Jefferies 2020 Virtual Healthcare ConferenceGlobeNewsWire • 06/01/20
Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 PatientsGlobeNewsWire • 05/07/20
Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical TrialsGlobeNewsWire • 04/13/20
Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe SepsisGlobeNewsWire • 03/18/20
Israel Patent Office Grants New Patent Covering Enlivex’s Allocetra Immunotherapy TreatmentGlobeNewsWire • 03/09/20